drugset / Trial / NCT00467779
Study of Cobimetinib in Participants With Solid Tumors
Non-randomizedParallel-groupOpen-labelTreatment
Summary
This non-randomized, open-label, study will determine the highest safe dose of cobimetinib, how often it should be taken, how well participants with cancer tolerate cobimetinib and will assess the pharmacokinetic effect of midazolam and dextromethorphan on the study drug.
Timeline
- Start
- 2007-05
- Primary completion
- 2014-04
- Completion
- 2014-04
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Cobimetinib | Small molecule | 0.05 mg/kg | Oral |
| Subject | Cobimetinib | Small molecule | 60 mg | Oral |
| Subject | Dextromethorphan | Unknown | 30 mg | — |
| Subject | Midazolam | Small molecule | 2 mg | — |